Protocols: Infinity hunts up a buyer for its disappointing cancer drug duvelisib; Is Northwest Bio finally broke?
AbbVie’s decision to abruptly pull out of its partnership with Infinity on duvelisib largely wrecked the company’s hopes to finally make it big after repeated setbacks over the years. But Infinity CEO Adelene Perkins isn’t giving up. She tells BioWorld that the company is pushing ahead in search of an accelerated approval – the drug hit its endpoint but looked commercially feeble – while scouting for another company willing to buy it. “We have several parties who are interested [in duvelisib] and we’re in discussions,” Perkins told the news group.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.